Jonathan Moreira, MD

Pembrolizumab

Brentuximab Vedotin

laboratory biomarker analysis

lenalidomide

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

5 unique interventions2 categories

Analytics

Trial Phases

Phase 22

Trial Status

Completed1

Other1

Role Distribution

Principal Investigator2

PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT04795869Phase 2Withdrawn

Recurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular T-Cell Lymphoma+11 more

PrincipalinvestigatorStart date: 2020-03-01

NCT02232516Phase 2Completed

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+14 more

PrincipalinvestigatorStart date: 2015-06-11

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Adult Nasal Type Extranodal NK/T-cell Lymphoma1 Lymphoma, Large-Cell, Anaplastic1 Angioimmunoblastic T-cell Lymphoma1 Hepatosplenic T-cell Lymphoma1 Lymphoma, T-Cell, Peripheral1 Recurrent Angioimmunoblastic T-Cell Lymphoma1 Recurrent Enteropathy-Associated T-Cell Lymphoma1 Recurrent Follicular T-Cell Lymphoma1

Affiliations

Northwestern University

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

12 trials

Shared therapeutic areas:

Adult Nasal Type Extranodal NK/T-cell LymphomaLymphoma, Large-Cell, AnaplasticAngioimmunoblastic T-cell Lymphoma+6 more

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score9%

Thomas E. Witzig, MD

Mayo Clinic

12 trials

Shared therapeutic areas:

Lymphoma, Large-Cell, AnaplasticAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score3%

Jun Zhu, MD

Peking University Cancer Hospital & Institute

12 trials

Shared therapeutic areas:

Lymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic

Similarity Score2%

Beata Holkova, MD

Massey Cancer Center

3 trials

Shared therapeutic areas:

National Cancer Institute (NCI)

Worked with same sponsors:

Eliot Epner, MD

Penn State Hershey Cancer Institute

Shared therapeutic areas:

Maria Delioukina, MD

City of Hope National Medical Center, USA

Shared therapeutic areas:

Peter Brown, MD

H:S Rigshospitalet, Department of Hematology, Denmark

Shared therapeutic areas:

Madeleine Duvic, MD

UT - M. D. Anderson Cancer Center

Shared therapeutic areas:

Fernando Camacho, MD

Bronx River Medical Associates, PC

Shared therapeutic areas:

Andrei Shustov, MD

Fred Hutchinson Cancer Research Center - Seattle Cancer Care Alliance

Shared therapeutic areas: